A recent study showed that PD-L1 expression on tumor cells in combination with CD8+ T-cell density were predictive biomarkers in patients with inoperable locally advanced NSCLC treated with concurrent chemoradiotherapy. The gene discussed is CD8A; the disease is neoplasm.